Try our Advanced Search for more refined results
Life Sciences
-
January 06, 2026
RFK Jr. Can't Avoid Medical Groups' Challenge To Vax Policy
A Boston federal judge on Tuesday rebuffed U.S. Health and Human Services Secretary Robert F. Kennedy Jr.'s bid to dismiss a challenge to vaccine policy changes, saying medical associations have plausibly alleged a federal vaccine committee is not fairly balanced.
-
January 06, 2026
NJ Judge Signals Green Light To Revive J&J Unit's Libel Suit
A New Jersey federal judge has indicated she is planning to grant a bankrupt Johnson & Johnson talc subsidiary's bid to revive its trade libel claim over a scientific article linking asbestos in talc to mesothelioma.
-
January 06, 2026
Public Health Atty Talks Botulism, Infants And FDA Staffing
Three years ago, a bacterial outbreak at a Michigan manufacturing plant sparked a shutdown and a national infant formula shortage. Another episode last year at a formula plant in Iowa should be a red flag for the public and a short-handed FDA, according to Sarah Sorscher of the Center for Science in the Public Interest.
-
January 06, 2026
Drugmakers Fight Multifront Legal Battles Over GLP-1s
In the wake of U.S. Food and Drug Administration approvals for GLP-1 weight-loss drugs, surging public demand and massive profits have inspired a broad range of drugmaker litigation against competitors, alleged counterfeits and telehealth providers.
-
January 06, 2026
Wyo. High Court Strikes Down 2 Laws Restricting Abortion
The Wyoming Supreme Court struck down the state's near-total abortion ban and a first-of-its-kind prohibition on abortion pills on Tuesday, saying the laws violated the state constitution.
-
January 06, 2026
Ill. Judge Trims Most Of Walgreens Shareholder Suit
An Illinois federal judge on Monday dismissed most claims in a lawsuit alleging Walgreens inflated share prices by concealing the lack of viability of its pharmacy division and primary care investment, warning shareholders not to "waste judicial resources" in amending their allegations by claiming straightforward statements are misleading "absent a coherent argument as to why."
-
January 06, 2026
Healthcare Litigator Moves Practice To Troutman In Philly
A litigator specializing in healthcare and product liability cases has joined Troutman Pepper Locke LLP's Philadelphia office after practicing for more than six years with Campbell Conroy & O'Neil PC.
-
January 06, 2026
Federal Prosecutor Rejoins King & Spalding In Atlanta
A former federal prosecutor who left King & Spalding LLP five years ago for an assistant U.S. attorney role has returned to the firm as an Atlanta-based partner in its product liability and mass torts practice, according to a Tuesday announcement.
-
January 06, 2026
Top Personal Injury, Medical Malpractice Cases Of 2025
A headline-grabbing $329 million wrongful death verdict against Tesla and a landmark $2.5 billion deal between DuPont and New Jersey over PFAS "forever chemicals" are among Law360's top personal injury and medical malpractice cases from 2025.
-
January 05, 2026
1st Circ. Upholds Block On Trump Admin NIH Funding Cuts
The First Circuit on Monday affirmed a Massachusetts federal judge's order permanently blocking the Trump administration from gutting National Institutes of Health funding for biomedical research, agreeing that the government didn't have the authority to cap indirect costs for research grants.
-
January 05, 2026
Fed. Circ. Examines Timing Of $452M Trade Secrets Suit
A Federal Circuit panel delved into the statute of limitations for trade secrets cases Monday, pressing an attorney for a South Korean company seeking to reverse a verdict that prompted a $452 million jury award to explain why the clock should start when a plaintiff suspects misappropriation rather than when it is actually discovered.
-
January 05, 2026
Express Scripts Wants FTC Atty Views On Insulin Prices
Express Scripts is seeking to force an attorney from the Federal Trade Commission to sit for a deposition in the agency's case accusing pharmacy benefit managers of inflating insulin prices, saying the commission's own attorneys acknowledge that manufacturers cause higher prices.
-
January 05, 2026
Cancer Biotech Co. Eyes $182M IPO
A company developing new drugs for treating cancer disclosed Monday it is looking to raise roughly $182 million in an initial public offering guided by Paul Hastings LLP and Davis Polk & Wardwell LLP, teeing it up for the first major IPO of 2026.
-
January 05, 2026
Aetna Drug Price-Fixing Suit Against Pharma Cos. Paused
A judge has paused Aetna Inc.'s Connecticut Superior Court lawsuit accusing nearly two dozen pharmaceutical companies of fixing the prices of generic drugs, refusing drugmakers' bids to dismiss the case but agreeing to put it on hold pending the outcomes of similar cases in other jurisdictions.
-
January 05, 2026
3rd Circ. Won't Rethink Tax On Interest In $191M Pharma Deal
The Third Circuit declined to reconsider its decision that a pharmaceutical company's $191 million payment settling a family feud was for the sale of a family trust's ownership shares and included interest that should be taxed as ordinary income.
-
January 05, 2026
Health Officials Roll Back Child Vaccine Recommendations
Amid public outcry, federal health officials on Monday revised vaccine recommendations for American children, cutting the number from 18 to 11 and bringing the United States in line with other developed countries such as Denmark.
-
January 05, 2026
Ind. Sues Eli Lilly Over 'Grossly Inflated' Insulin Prices
Indiana's attorney general on Monday announced a state court suit against Eli Lilly alleging it schemed to artificially inflate the price of insulin, saying the litigation follows two years of ultimately unsuccessful attempts to resolve the matter without litigation against the drug manufacturer.
-
January 05, 2026
Trump Backs Biden's Medicare Drug Price Law At High Court
The Trump administration is defending the Biden-era Medicare Drug Price Negotiation program to the U.S. Supreme Court, asking the justices to deny AstraZeneca's petition challenging the program as unconstitutional.
-
January 05, 2026
Thesis Supplements Illegally Sold As ADHD Drugs, Suit Says
A Louisiana woman is suing the owner of Thesis Nootropics in New York federal court, alleging that the company's line of supplements is illegally marketed as an alternative to Adderall and other medications despite lacking federal approval.
-
January 05, 2026
Paul Hastings Adds Hogan Lovells Duo To Life Sciences Team
Two longtime Hogan Lovells partners, including the head of its pharmaceutical and biotechnology regulatory practice, have joined Paul Hastings LLP in Washington, D.C., the firm announced Monday.
-
January 02, 2026
Catching Up With Delaware's Chancery Court
Delaware's Court of Chancery paddled through mostly calm waters at the year's end, with plenty of big hearings and decisions in its rearview mirror, including a recent Chancery reversal restoring Elon Musk's compensation package, earlier valued at $56 billion.
-
January 02, 2026
IRS Floats Updates To Fee Paid By Brand Drugmakers
The Internal Revenue Service floated updates to regulations governing how branded prescription drug manufacturers or importers should calculate an annual fee established by the Affordable Care Act, a move the agency said aims to incorporate changes in drug discount programs and clarify tax reporting.
-
January 02, 2026
Drug Pricing Battles To Watch In 2026
With drugmakers already pushing back on drug affordability programs and policies, Law360 looks at the year ahead for litigation focused on state and federal drug pricing programs.
-
January 02, 2026
Product Liability Cases To Watch In 2026
Trials in the massive litigation against social media giants like Facebook are set to start in the New Year, as litigants battle over whether the companies should be held responsible for allegedly designing their platforms to addict youth, causing a bevy of mental health harms, and cases against popular weight loss drugs like Ozempic continue to mount. Here's what else product liability attorneys will be watching in 2026.
-
January 02, 2026
Patent Litigation Trends To Watch In 2026
Attorneys are expecting a significant increase in district court litigation after a series of dramatic changes at the U.S. Patent and Trademark Office have made the Patent Trial and Appeal Board less attractive, which is one of the most significant trends for 2026.
Expert Analysis
-
From Clerkship To Law Firm: 5 Transition Tips For Associates
Excerpt from Practical Guidance
Transitioning from a judicial clerkship to an associate position at a law firm may seem daunting, but by using knowledge gained while clerking, being mindful of key differences and taking advantage of professional development opportunities, these attorneys can flourish in private practice, say attorneys at Lowenstein Sandler.
-
9th Circ.'s Trade Secrets Ruling Is A Win For DTSA Plaintiffs
The Ninth Circuit's recent decision in Quintara v. Ruifeng shifts the balance in federal trade secret litigation toward a more flexible, discovery-driven process, meaning that plaintiffs may be more likely to pursue claims under the Defend Trade Secrets Act, and early motions to strike or dismiss will face steep odds, say attorneys at Cooley.
-
Associates Can Earn Credibility By Investing In Relationships
As the class of 2025 prepares to join law firms this fall, new associates must adapt to office dynamics and establish credible reputations — which require quiet, consistent relationship-building skills as much as legal acumen, says Kyle Forges at Bast Amron.
-
Puzzling Out When Similar Insurance Claims Are Related
A recent decision in Virginia federal court shows that more than identical allegations of negligent business practices across two lawsuits may be necessary to satisfy the strict definition of relatedness under claims-made liability insurance policies, say attorneys at Hunton.
-
A Shifting Trend In FDA Form 483 Disclosure Obligations
A New York federal court's Checkpoint Therapeutics decision extends a recent streak of dismissals of securities class actions alleging that pharmaceutical companies failed to disclose U.S. Food and Drug Administration Form 483 inspection reports, providing critical guidance for companies during the FDA approval process, say attorneys at Alston & Bird.
-
Trending At The PTAB: IPR Memo And Its Fed. Circ. Backdrop
There are new rules for when and how evidence other than patents or printed publications can be considered in inter partes reviews, and while this change is intended to reflect current Federal Circuit precedent, the U.S. Patent and Trademark Office's memo seems to acknowledge tension with last month's Shockwave decision, say attorneys at Finnegan.
-
Lessons From 7th Circ.'s Deleted Chat Sanctions Ruling
The Seventh Circuit’s recent decision in Pable v. Chicago Transit Authority, affirming the dismissal of an ex-employee’s retaliation claims, highlights the importance of properly handling the preservation of ephemeral messages and clarifies key sanctions issues, says Philip Favro at Favro Law.
-
Breaking Down The Proposed Hemp Bill
A proposed bill in the U.S. House of Representatives, recently approved by the House Appropriations Committee, contains a rider that would significantly change the definition of hemp and dramatically reshape the current hemp-derived product market, say attorneys at King & Spalding.
-
Assessing Federal Securities Class Action Stats In '25 So Far
The settlement amount as a percentage of damages in securities class actions has continued to decline in the first half of 2025, a trend that may be important for assessing exposure and risk in future securities litigation, say analysts at Analysis Group.
-
Series
Quilting Makes Me A Better Lawyer
Turning intricate patterns of fabric and thread into quilts has taught me that craftsmanship, creative problem-solving and dedication to incremental progress are essential to creating something lasting that will help another person — just like in law, says Veronica McMillan at Kramon & Graham.
-
How Agentic AI Is Testing The Limits Of Patent Law
While a recent Swiss court ruling suggests that human-centric rules regarding inventorship will likely remain in place for the near future, it captures a core tension confronting patent systems worldwide as the technology producing patent-worthy ideas is becoming increasingly autonomous, says Matthew Carey at Marshall Gerstein.
-
How To Prep For Potential Passage Of SAFER Banking Act
The Secure and Fair Enforcement Regulation, or SAFER, Banking Act, could fundamentally reshape how financial institutions interact with cannabis businesses, so operators that move now to get their house in order will be best positioned to capitalize if and when change comes, says Alex Leonowicz at Howard & Howard.
-
A Former PTAB Judge Weighs The End Of Remote Hearings
Former Patent Trial and Appeal Board Judge Amanda Wieker, now at McGuireWoods, examines the costs and benefits of the PTAB's impending in-person hearing requirement, and offers suggestions for making the most out of this new regime.
-
The Future Of Lab-Test Regs After FDA Rescinds Rule
The U.S. Food and Drug Administration recently rescinded its laboratory-developed tests rule in response to a Texas federal court decision this spring, reinforcing a separation of authority between the FDA and the Centers for Medicare & Medicaid Services, and calling into question the FDA's role in overseeing such tests without congressional action, say attorneys at Venable.
-
SDNY Ruling Reinforces Joint Steering Committee Obligations
The recent Southern District of New York decision in ChemImage v. Johnson & Johnson makes joint steering committees a valuable tool in strategic relationships, as provisions for such committees can now be wielded to demand attention to core issues, say Lisa Bernstein at the University of Chicago Law School, and Reginald Goeke and Brad Peterson at Mayer Brown.